Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 381

Similar articles for PubMed (Select 12679756)

1.

Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.

Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW; THE-PRINCE Study Group.

Am Heart J. 2003 Apr;145(4):614-21.

PMID:
12679756
3.

Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group.

Circulation. 2004 Mar 2;109(8):997-1003. Epub 2004 Feb 16.

4.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
5.

The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.

Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O'Riordan W, Pineo GF; PREVAIL Investigators.

Lancet. 2007 Apr 21;369(9570):1347-55.

PMID:
17448820
6.

Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.

Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M.

Acta Neurol Scand. 2002 Aug;106(2):84-92.

PMID:
12100367
7.

Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.

De A, Roy P, Garg VK, Pandey NK.

Blood Coagul Fibrinolysis. 2010 Jan;21(1):57-61. doi: 10.1097/MBC.0b013e3283333505.

PMID:
19844176
8.

Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Schädlich PK, Kentsch M, Weber M, Kämmerer W, Brecht JG, Nadipelli V, Huppertz E.

Pharmacoeconomics. 2006;24(6):571-91.

PMID:
16761905
10.

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW; Matisse Investigators.

J Thromb Haemost. 2007 Jun;5(6):1191-4.

PMID:
17403087
11.

Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.

Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH; ASTH DVT Study Group.

J Thromb Thrombolysis. 2005 Jun;19(3):173-81.

PMID:
16082604
12.

Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.

Schädlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG.

Am J Cardiovasc Drugs. 2007;7(3):199-217.

PMID:
17610347
13.

[The risk of bleeding associated with low molecular weight heparin in patients with renal failure].

Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.

G Ital Nefrol. 2010 Nov-Dec;27(6):649-54. Italian.

PMID:
21132647
15.

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators.

J Thromb Haemost. 2006 Jun;4(6):1246-52.

PMID:
16706967
17.
18.

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.

Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG.

Blood Coagul Fibrinolysis. 2003 Jun;14(4):341-6.

PMID:
12945875
19.

A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.

Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL.

Chin Med J (Engl). 2006 Mar 5;119(5):355-9.

PMID:
16542576
20.

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.

Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B Investigators.

Am Heart J. 2003 Jul;146(1):33-41.

PMID:
12851605
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk